BIOMAT Database Logo BIOMAT Database Logo

Treatment outcome in juvenile-onset myasthenia gravis. 2019

Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Department of Neurology, Medical University of Warsaw, 1A Banacha Street, 02-097, Warsaw, Poland.

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Approximately 10%-15% of MG patients have juvenile (<18 years of age) onset. We aimed to assess the clinical course, outcome, and subjectively perceived health status of a cohort of juvenile MG patients. This was a retrospective analysis of medical records of 101 patients followed by a cross-sectional questionnaire study. The mean age of patients was 12.8 years at onset and 13.7 years at diagnosis. Ninety percent of the patients were seropositive. Over 40% of the patients were treated with immunosuppression and over 80% underwent thymectomy. The mean Myathenia Gravis Activities of Daily Living (MG-ADL) scale score was 2.48. At last follow-up, 30.9% of patients were in complete, stable remission; 77.8% perceived their health as good. The treatment outcome for juvenile MG is favorable, with a marked reduction of symptoms and good day-to-day activity achieved for most patients. Muscle Nerve 59:549-549, 2019.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010956 Plasmapheresis Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004576 Electromyography Recording of the changes in electric potential of muscle by means of surface or needle electrodes. Electromyogram,Surface Electromyography,Electromyograms,Electromyographies,Electromyographies, Surface,Electromyography, Surface,Surface Electromyographies

Related Publications

Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Juvenile myasthenia gravis with prepubertal onset.
December 1998, Neuromuscular disorders : NMD,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Prematurity and early-onset juvenile myasthenia gravis.
January 1992, Pediatric neurology,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis.
July 1994, Neurology,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
[Treatment of juvenile myasthenia gravis].
January 2019, Medicina,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
[Treatment of Juvenile Myasthenia Gravis].
January 2024, Brain and nerve = Shinkei kenkyu no shinpo,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Outcome measures and treatment effectiveness in late onset myasthenia gravis.
January 2020, Neurological research and practice,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
February 2020, Acta neurologica Belgica,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Immunosuppressive treatment for juvenile myasthenia gravis.
March 1992, European journal of pediatrics,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
"Juvenile myasthenia gravis".
June 1978, Indian pediatrics,
Aleksandra Jastrzębska, and Miłosz Jastrzębski, and Barbara Ryniewicz, and Anna Kostera-Pruszczyk
Juvenile myasthenia gravis.
July 1980, Neurology,
Copied contents to your clipboard!